WO2002000168A3 - Combination hiv therapy including camptothecin - Google Patents

Combination hiv therapy including camptothecin Download PDF

Info

Publication number
WO2002000168A3
WO2002000168A3 PCT/US2001/019863 US0119863W WO0200168A3 WO 2002000168 A3 WO2002000168 A3 WO 2002000168A3 US 0119863 W US0119863 W US 0119863W WO 0200168 A3 WO0200168 A3 WO 0200168A3
Authority
WO
WIPO (PCT)
Prior art keywords
camptothecin
inhibitors
combination
therapy including
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019863
Other languages
French (fr)
Other versions
WO2002000168A2 (en
Inventor
Gerald Schochetman
Lucy Chang
Joseph Rubinfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Pharmaceuticals Inc
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Priority to AU2001268653A priority Critical patent/AU2001268653A1/en
Priority to EP01946632A priority patent/EP1311266A2/en
Publication of WO2002000168A2 publication Critical patent/WO2002000168A2/en
Anticipated expiration legal-status Critical
Publication of WO2002000168A3 publication Critical patent/WO2002000168A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method is provided for treating HIV infection using a combination therapy which includes a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, precursor of 20(S)-camptothecin and metabolite of 20(S)-camptothecin, in combination with a cocktail of antiretroviral drugs such as nucleoside reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors. The method comprises administering highly active antiretroviral therapy (HAART); and co-administering to the HIV-infected host therapeutically effective amount of a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, precursor of 20(S)-camptothecin and metabolite of 20(S)-camptothecin.
PCT/US2001/019863 2000-06-28 2001-06-20 Combination hiv therapy including camptothecin Ceased WO2002000168A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2001268653A AU2001268653A1 (en) 2000-06-28 2001-06-20 Combination hiv therapy including camptothecin
EP01946632A EP1311266A2 (en) 2000-06-28 2001-06-20 Combination hiv therapy including camptothecin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60696700A 2000-06-28 2000-06-28
US09/606,967 2000-06-28

Publications (2)

Publication Number Publication Date
WO2002000168A2 WO2002000168A2 (en) 2002-01-03
WO2002000168A3 true WO2002000168A3 (en) 2003-03-13

Family

ID=24430261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019863 Ceased WO2002000168A2 (en) 2000-06-28 2001-06-20 Combination hiv therapy including camptothecin

Country Status (4)

Country Link
US (1) US20040116411A1 (en)
EP (1) EP1311266A2 (en)
AU (1) AU2001268653A1 (en)
WO (1) WO2002000168A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365833B1 (en) 2000-06-28 2008-04-29 Delta E System for measuring radiance, transmittance and reflectance
EP1355634B8 (en) 2000-11-09 2009-03-04 Neopharm, Inc. Sn-38 lipid complexes and methods of use
WO2003030864A1 (en) 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
TWI351284B (en) * 2004-04-09 2011-11-01 Chugai Pharmaceutical Co Ltd Novel water-soluble prodrugs
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
FR2903312B1 (en) 2006-07-05 2008-09-26 Univ Aix Marseille Ii USE OF INHIBITORS OF HMG-COA REDUCTASE AND FARNESYL-PYROPHOSPHATE SYNTHASE IN THE PREPARATION OF A MEDICINAL PRODUCT
WO2008088806A1 (en) * 2007-01-16 2008-07-24 Johns Hopkins University Combinational paradigm combating hiv, hiv/hsv, or hiv/hpv infections in humans using small molecular weight compounds from plants
CN103372215B (en) * 2008-01-03 2016-03-09 艾克斯-马赛大学 The compositions used during anti-hiv therapy and method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
WO1997044492A1 (en) * 1996-05-23 1997-11-27 The Rockefeller University Treatment of hiv infection by interfering with host topoisomerase interaction with hiv gag and rt

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
US5422344A (en) * 1990-05-08 1995-06-06 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Method of treating retroviral infections in mammals
US5641773A (en) * 1993-11-30 1997-06-24 Dana-Farber Cancer Institute Methods for treating viral infections
US5874430A (en) * 1996-10-02 1999-02-23 Dupont Pharmaceuticals Company 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011005A2 (en) * 1994-10-06 1996-04-18 Atlas Leon T Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
WO1997044492A1 (en) * 1996-05-23 1997-11-27 The Rockefeller University Treatment of hiv infection by interfering with host topoisomerase interaction with hiv gag and rt

Also Published As

Publication number Publication date
EP1311266A2 (en) 2003-05-21
US20040116411A1 (en) 2004-06-17
WO2002000168A2 (en) 2002-01-03
AU2001268653A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DK1293207T3 (en) Use of ritonavir (ABT-538) to improve the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
CA2467490A1 (en) Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
NO911854D0 (en) PROCEDURE FOR THE PREPARATION OF PEPTID DERIVATIVES.
EP1564210A4 (en) 4-OXOQUINOLINIC COMPOUNDS AND THEIR USE AS INHIBITORS OF HIV-INTEGRASE
CA2455774A1 (en) Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
EP1308439A8 (en) Proline derivatives and use thereof as drugs
EP2033954A4 (en) 6-(heterocycle-substituted benzyl)-4-oxoquinoline compound and use of the same as hiv integrase inhibitor
WO2002000168A3 (en) Combination hiv therapy including camptothecin
WO2002034284A3 (en) Methods of therapy for hiv infection
WO2002009639A3 (en) Methods and pharmaceutical compositions for healing wounds
HUP0103819A3 (en) Crystalline efavirenz pharmaceutical compositions containing it as active ingredient, and use of efavirenz for making medicament available for inhibitions of reverse transcriptase and for treating hiv infection
WO2003059246A3 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
BR0317095A (en) Use of a combination containing a non-nucleoside (nnrti) reverse transcriptase inhibitor with a cytochrome p450 inhibitor such as protease inhibitors
WO2003013424A3 (en) Use of r-nsaid compounds for anti-hiv treatment
ZA991029B (en) Composition and methods for treatment of hiv infections.
EA199700150A1 (en) COMBINED TREATMENT WITH RESPECT OF HIV INFECTION USING HIV PROTASE INHIBITOR INDINAVIAR AND REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, ddI OR ddC
IE894050L (en) Compound with gastric acid inhibitory effect and process for¹its preparation
WO2001034177A3 (en) Method of treating a viral infection using antagonists of macrophage colony stimulating factor
WO2003016266A1 (en) β-KETOAMIDE COMPOUNDS AND MEDICINAL USE THEREOF
WO2005048978A3 (en) A controlled release pharmaceutical composition and a process for preparing the same
WO2001019357A3 (en) Combination preparation for the treatment of sexual dysfunction
WO1990004977A3 (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
HK1041444A1 (en) Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
NO20002481L (en) Combination therapy for the treatment of AIDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001946632

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001946632

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001946632

Country of ref document: EP